Invivyd News

Invivyd (IVVD.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.38 dollars, previous value was -0.32 dollars, and expected value was -0.38 dollars.

Invivyd (IVVD.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.38 dollars, previous value was -0.32 dollars, and expected value was -0.38 dollars.

Zhitong Finance06:50

Invivyd | 10-Q: Quarterly report

Futu News04:53 · Announcements

Invivyd 1Q Loss/Shr 38c >IVVD

Invivyd 1Q Loss/Shr 38c >IVVD

Dow Jones04:08

Press Release: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Launched PEMGARDA(TM) in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and ad

Dow Jones04:01

Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback

Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback

BenzingaMay 7 19:39

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a

GlobeNewswireMay 3 05:13

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects to end 2024 with at

GlobeNewswireApr 30 19:30

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes From the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid represents

GlobeNewswireApr 15 19:30

Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering

Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering

BenzingaApr 12 19:33

Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD

Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD

Dow JonesApr 12 19:31

Press Release: Invivyd Announces CEO Transition

Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to prot

Dow JonesApr 12 19:30

Invivyd Appoints Jeremy Gowler Interim CEO >IVVD

Invivyd Appoints Jeremy Gowler Interim CEO >IVVD

Dow JonesApr 12 19:30

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)

TipRanksApr 9 00:10

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Yahoo FinanceApr 7 21:47

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Invivyd (NASDAQ:IVVD) shareholders have done very well over the last year, with the share price soaring

Simply Wall StApr 5 23:25

Invivyd Raised to Buy From Neutral by Guggenheim

Invivyd Raised to Buy From Neutral by Guggenheim

Dow JonesApr 5 20:23

Invivyd Shares Are Trading Higher After the Company Announced PEMGARDA Is Available for Purchase in the U.S. and Said It Sees Initial FY24 PEMGARDA Net Product Revenue Guidance in the Range of $150 Million to $200 Million.

Invivyd Shares Are Trading Higher After the Company Announced PEMGARDA Is Available for Purchase in the U.S. and Said It Sees Initial FY24 PEMGARDA Net Product Revenue Guidance in the Range of $150 Mi

BenzingaApr 5 20:19

Guggenheim Upgrades Invivyd to Buy, Announces $9 Price Target

Guggenheim analyst Evan Wang upgrades Invivyd from Neutral to Buy and announces $9 price target.

Analyst UpgradesApr 5 20:13

Invivyd Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 132.56% Guggenheim → $9 Upgrades Neutral → Buy 03/26/2024 158.4% Morgan Stanley $4 → $10 Upgrad

BenzingaApr 5 20:12

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura Sushi USA, Inc. (NASDAQ:KRUS) climbed 6% to $110.11 in pre-market trading foll

BenzingaApr 5 20:01